HTBX

Heat Biologics, Inc. Common Stock NASDAQ Capital Market
$7.2
Open: $7.04 High: $7.38 Low: $6.871 Close: $7.15
Range: 2021-06-23 - 2021-06-24
Volume: 754,579
Market: Open
Powered by Finage Stock APIDelayed data
HTBX
Heat Biologics, Inc. Common Stock 801 Capitola Drive Durham NC, 27713 http://www.heatbio.com
Heat Biologics Inc is a US-based immuno-oncology company. It is engaged in developing therapies which activate a patient's immune system against cancer utilizing an engineered form of gp96.
  • CEO: Jeffrey Wolf
  • Employees: 19
  • Sector: Healthcare
  • Industry: Biotechnology
HTBX News
Latest news about the HTBX
  • Heat Biologics Announces Significant Expansion of R&D and Pre-Clinical Capabilities at Corporate Headquarters

    Investments expected to accelerate development timelines and reduce development expensesDURHAM, N.C., June 23, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced the expansion of its research and development facilities in Morrisville, North Carolina. The expansion w

    View More →
  • Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients at 2021 American Society of Clinical Oncology Annual Meeting

    Survival benefit observed in two treatment settings of previously treated non-small lung cancer patientsDURHAM, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Dr. Roger B. Cohen, MD, Professor of Medicine at the University of Pennsylvania Perelman School of Medicine, presented an overview of the latest HS-110 data at the 2021

    View More →
  • HTBX: 1Q:21 Results

    By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT First Quarter 2021 Results Heat Biologics, Inc. (NASDAQ:HTBX) reported first quarter 2021 results on May 5, 2021, concurrent with the submission of Form 10-Q to the SEC. Highlights for the first quarter ending March 31, 2021 and to-date include: ➢ Appointment of William Ostrander as CFO - January 2021 ➢ Commencement of

    View More →
  • Heat Biologics Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer; Selected for Presentation at 2021 American Society of Clinical Oncology Annual Meeting

    DURHAM, N.C., May 20, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that the latest data from HS-110, the Company’s lead product, has been accepted for poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held virtually from June 4-8, 2021. The ASCO Annual Meeting is the largest international conference to showcase the latest advancements in oncology. Abstract Title: Interim results of viagenpumatucel-L (HS-110) plus nivolumab in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC) in two treatment settings Session Title: Poster Session: Lung Cancer—Non-Small Cell Metastatic Abstract Number: 9100 Lead Author and Presenter: Roger B. Cohen, MD, Perelman School of Medicine at the University of Pennsylvania According to ASCO, more than 5,400 abstracts were reviewed for the 2021 ASCO Annual Meeting. Additional information about the conference may be accessed at https://conferences.asco.org/am/attend. About HS-110HS-110 is a first-in-class, off-the-shelf, allogeneic cell therapy designed to utilize gp96 for immune activation against multiple tumor testis antigens. Phase 2 trial of HS-110 in combination with Bristol-Myers Squibb's (BMS) OPDIVO® (nivolumab) has completed enrollment in patients with incurable or metastatic NSCLC. OPDIVO® is a programmed death-1 immune checkpoint inhibitor (PD-1 inhibitor). HS-110 has broad potential for providing multiple treatment options to NSCLC patients in combination with a PD-1 inhibitor. Positive interim survival data has been demonstrated in two distinct treatment settings in previously treated NSCLC patients who have not been treated with PD-1 inhibitor or programmed death-ligand 1 inhibitor (PD-L1 inhibitor) as well as patients who have progressed during or after previous treatment with a PD-1 or PD-L1 [PD-(L)1] inhibitor. Combination of HS-110 and PD-(L)1 therapies may confer additional survival benefit. About Heat Biologics, Inc.Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. Heat’s gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials. Forward Looking StatementThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectation, and assumptions and include statements such as the broad potential of HS-110 for providing multiple treatment options to NSCLC patients in combination with a PD-1 inhibitor. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, Heat's vaccine platform to provide protection against COVID-19, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, especially in light of COVID-19, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat's most recent annual report on Form 10-K filed with the SEC, and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law. Media and Investor Relations ContactDavid Waldman+1 919 289 4017investorrelations@heatbio.com

    View More →
  • Heat Biologics Announces Multiple Presentations on PTX-35 at the Upcoming 3rd Annual Treg Directed Therapies Summit

    DURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that PTX-35 will be featured in several presentations and panel discussions at the 3rd Annual Treg Directed Therapies Summit on May 19-20. PTX-35 is a novel, potential first-in-class antibody modulating TNFRSF25 (death receptor 3 or DR3), a receptor that is preferentially expressed by antigen-experienced T-cells. On Wednesday, May 19th at 4PM EDT, Heat Biologics will present: “A Novel TNFRSF25-Agonist for Regulatory T-Cell Expansion.” The presenter, Matthew Seavey, Ph.D., Heat Biologics’ Executive Director of Special Projects, plans to discuss how TNFRSF25-engagement by PTX-35 can expand regulatory T-cells in vivo and reduce disease severity in several animal models of GVHD & inflammatory disease.On Thursday, May 20th at 3:30PM EDT, Robert B. Levy, Ph.D., Professor of Microbiology and Immunology at the University of Miami Miller School of Medicine, will present: “Improving Outcomes of Allo-HCT: Manipulating the Regulatory Cell Compartment in vivo to Ameliorate GVHD.”Dr. Seavey will also chair two panels, including: “Exploring Key Questions to Advance Understanding of Treg Behavior,” and “Maximizing Immune Tolerance through Generation of Antigen Specific Tregs.” The 3rd Annual Treg Directed Therapies Summit is focused on targeting and translating Treg modifying therapies and brings together executives and leading researchers from large pharma, biotech and academia to discuss developments in Treg therapies. About PTX-35PTX-35 is a novel, potential first-in-class antibody modulating TNFRSF25 (death receptor 3 or DR3), a receptor that is preferentially expressed by antigen-experienced T-cells. PTX-35 is currently enrolling in a Phase 1 clinical trial for the treatment of patients with solid tumors. About Heat Biologics, Inc.Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. Heat’s gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials. Forward Looking StatementThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectation, and assumptions and include statements such as the planned presentations. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the contributions of, the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, Heat's vaccine platform to provide protection against COVID-19, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, especially in light of COVID-19, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat's most recent annual report on Form 10-K filed with the SEC, and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law. Media and Investor Relations ContactDavid Waldman+1 919 289 4017investorrelations@heatbio.com

    View More →
  • Heat Biologics Appoints Anthony Manning, Ph.D. as Chief Scientific Advisor

    DURHAM, N.C., May 10, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced the appointment of Anthony Manning, Ph.D. as Chief Scientific Advisor. Dr. Manning will be responsible for strategic initiatives to accelerate the development of Heat Biologics’ product portfolio. Dr. Manning brings over three decades of experience in immunology and autoimmune disease research and development. Most recently, Dr. Manning served as Chief Scientific Officer and Head of Research at Momenta Pharmaceuticals, a biotechnology company focused on biologic therapeutics to treat rare immune-mediated diseases. At Momenta, Dr. Manning provided strategic leadership to all research activities, including the discovery and development of three novel autoimmune drug candidates. Momenta was recently acquired by Johnson & Johnson for approximately $6.5 billion. Prior to Momenta, Dr. Manning served as Senior Vice President of Research and Preclinical Development at Aileron Therapeutics, where he oversaw target selection, lead identification and optimization, clinical candidate selection, and IND-enabling studies. Before Aileron, Dr. Manning served as Vice President and Head of Inflammation and Autoimmune Disease Research at Biogen, and previously served as Vice President and Global Therapy Area Head of Inflammation, Autoimmunity & Transplantation Research at Roche. Dr. Manning is a member of the Board Directors of Palatin Technologies, Inc, Chairman of the Institute for Biomedical Entrepreneurship, and an Advisor to the Harvard Medical School Therapeutics Initiative. He is an author and inventor on over 120 publications and patents relating to autoimmune disease and novel drug discovery. Jeff Wolf, Chief Executive Officer of Heat Biologics, commented, “We are thrilled to welcome Dr. Manning to our team. With his proven track record in the drug discovery, research and development, Dr. Manning will provide strategic leadership and invaluable insight to accelerate the development of our portfolio programs. ” “I am excited to be joining Jeff and the team at Heat Biologics,” stated Dr. Manning. “My entire professional career has been aimed at targeting the immune system and Heat’s first-in-class pipeline holds immense promise for improving current standard of care. I look forward to working with the team to expand and advance the innovative pipeline programs.” About Heat Biologics, Inc.Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. Heat’s gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials. Forward Looking StatementThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectation, and assumptions and include statements such as Dr. Manning offering invaluable insight as Heat advances its product pipeline.. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the contributions of Dr. Manning to Heat, the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, Heat's vaccine platform to provide protection against COVID-19, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, especially in light of COVID-19, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat's most recent annual report on Form 10-K filed with the SEC, and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law. Media and Investor Relations ContactDavid Waldman+1 919 289 4017investorrelations@heatbio.com

    View More →
  • Heat Biologics Provides First Quarter 2021 Business Update; Reports Continued Progress on Oncology and COVID-19 Vaccine Programs

    DURHAM, N.C., May 05, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today provided financial, clinical and operational updates for the first quarter ended March 31, 2021. Jeff Wolf, Chief Executive Officer of Heat, commented, “We continue to make tremendous progress on our clinical programs, including both our oncology program and COVID-19 vaccine program, which we recently advanced into scale-up manufacturing. We are currently reviewing a variety of possible Phase 3 registration settings for HS-110 in combination with checkpoint inhibitors, following positive interim data from our Phase 2 trial in patients with advanced non-small cell lung cancer (NSCLC).” “We recently announced promising new preclinical data around PTX-35, our potential first-in-class T-cell co-stimulatory antibody at the AACR Annual Meeting 2021. We are completing enrollment in our Phase 1 PTX-35 trial in patients with solid tumors and expect to share interim data later this year.” “Finally, we have maintained a solid balance sheet with over $128 million of cash and short-term investments, which should provide us substantial runway to fund our current clinical programs and further expand our therapeutic portfolio. Moreover, we believe that upcoming catalysts and milestones have the potential to drive significant shareholder value in 2021,” concluded Mr. Wolf. First Quarter 2021 Financial Results Recognized $0.5 million of grant revenue for qualified expenditures under the CPRIT and NIH grant compared to $0.9 million of grant revenue for the same period last year. The decrease in grant revenue in the current-year period primarily reflects the expected timing of completion of deliveries under the current phase of the contracts. As of March 31, 2021, we had deferred revenue of $0.09 million for CPRIT proceeds received but for which the costs had not been incurred or the conditions of the award had not been met.Research and development expenses was $3.4 million and $2.8 million for the three months ended March 31, 2021 and 2020, respectively.General and administrative expense was $4.8 million and $3.3 million for the three months ended March 31, 2021 and 2020. The increase was primarily due to stock compensation expense.Net loss attributable to Heat Biologics was approximately $7.5 million, or ($0.31) per basic and diluted share for the quarter ended March 31, 2021 compared to a net loss of approximately of $6.3 million, or ($0.77) per basic and diluted share for the quarter ended March 31, 2020.As of March 31, 2021, the Company had approximately $132 million in cash, cash equivalents and short investments. About Heat Biologics, Inc.Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. Heat’s gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials. For more information, please visit: www.heatbio.com, and also follow us on Twitter. Forward Looking StatementThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectation, and assumptions and include statements such as sharing interim data later this year from the Phase 1 PTX-35 trial in patients with solid tumors, cash and short-term investments providing Heat a substantial runway to fund Heat’s current clinical programs and further expand Heat’s therapeutic portfolio, and upcoming catalysts and milestones having the potential to drive significant shareholder value in 2021. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the timing of providing interim data from the Phase 1 PTX-35 trial in patients with solid tumors, ability of Heat's vaccine platform to provide prevention and treatment of cancer and infectious diseases, such as COVID-19, the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, especially in light of COVID-19, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities and its cash and short-term investments providing significant runway to fund Heat’s current clinical programs and further expand Heat’s therapeutic portfolio, its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat's annual report on Form 10-K for the year ended December 31, 2020 filed with the SEC, and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law. Media and Investor Relations ContactDavid Waldman+1 919 289 4017investorrelations@heatbio.com (tables follow) HEAT BIOLOGICS, INC. Consolidated Balance Sheets March 31, December 31, 2021 2020 (unaudited) Current Assets Cash and cash equivalents$31,156,747 $10,931,890 Short-term investments 100,899,984 100,842,438 Accounts receivable 103,232 177,239 Prepaid expenses and other current assets 1,718,364 1,842,620 Total Current Assets 133,878,327 113,794,187 Property and Equipment, net 967,582 676,262 Other Assets In-process R&D 5,866,000 5,866,000 Goodwill 1,452,338 1,452,338 Operating lease right-of-use asset 1,947,192 2,035,882 Finance lease right-of-use asset 217,469 247,194 Deposits 141,201 122,779 Total Other Assets 9,624,200 9,724,193 Total Assets$144,470,109 $124,194,642 Liabilities and Stockholders' Equity Current Liabilities Accounts payable$792,545 $1,051,764 Deferred revenue, current portion 93,529 603,717 Operating lease liability, current portion 285,927 278,753 Finance lease liability, current portion 109,757 108,127 Accrued expenses and other liabilities 1,764,385 1,614,534 Total Current Liabilities 3,046,143 3,656,895 Long Term Liabilities Other long-term liabilities 43,754 36,243 Derivative warrant liability 42,481 33,779 Deferred tax liability 361,911 361,911 Deferred revenue, net of current portion 237,500 237,500 Operating lease liability, net of current portion 1,227,634 1,301,636 Financing lease liability, net of current portion 132,181 160,240 Contingent consideration, net of current portion 2,255,480 2,250,844 Contingent consideration, related party - net of current portion 663,035 661,671 Total Liabilities 8,010,119 8,700,719 Stockholders' Equity Common stock, $.0002 par value; 250,000,000 and 250,000,000 shares authorized, 25,137,410 and 22,592,500 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively 5,027 4,519 Additional paid-in capital 275,618,780 247,048,349 Accumulated deficit (138,179,663) (130,647,485)Accumulated other comprehensive loss (147,788) (166,056)Total Stockholders' Equity - Heat Biologics, Inc. 137,296,356 116,239,327 Non-Controlling Interest (836,366) (745,404)Total Stockholders' Equity 136,459,990 115,493,923 Total Liabilities and Stockholders' Equity$144,470,109 $124,194,642 HEAT BIOLOGICS INC.Consolidated Statements of Operations and Comprehensive Loss (unaudited) Three Months Ended March 31, 2021 2020 Revenue: Grant and contract revenue$538,645 $901,880 Operating expenses: Research and development 3,406,248 2,782,506 General and administrative 4,767,645 3,270,548 Change in fair value of contingent consideration 6,000 (27,000)Total operating expenses 8,179,893 6,026,054 Loss from operations (7,641,248) (5,124,174) Change in fair value of warrant liability (8,702) (977,710)Investor relations expense — (66,767)Interest income 195,165 52,710 Other expense, net (168,355) (257,479)Total non-operating income (loss) 18,108 (1,249,246) Net loss before income taxes (7,623,140) (6,373,420)Income tax expense — — Net loss (7,623,140) (6,373,420)Net loss - non-controlling interest (90,962) (81,314)Net loss attributable to Heat Biologics, Inc.$(7,532,178) $(6,292,106) Net loss per share, basic and diluted$(0.31) $(0.77) Weighted-average common shares outstanding, basic and diluted 24,199,916 8,183,154 Comprehensive loss: Net loss$(7,623,140) $(6,373,420)Unrealized gain on foreign currency translation 18,268 218,804 Total comprehensive loss (7,604,872) (6,154,616)Comprehensive loss attributable to non-controlling interest (90,962) (81,314)Comprehensive loss - Heat Biologics, Inc.$(7,513,910) $(6,073,302)

    View More →
  • A Look At Heat Biologics' (NASDAQ:HTBX) Share Price Returns

    Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut...

    View More →
  • HTBX: Cash, COVID and Clinical Data

    By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT Fourth Quarter and Fiscal Year 2020 Results Heat Biologics, Inc. (NASDAQ:HTBX) reported full year 2020 results on March 25, 2021 concurrent with the submission of Form 10-K to the SEC. 2020 was a productive year for Heat, advancing its COVID vaccine to scale-up manufacturing stage, generating favorable results from multiple

    View More →
  • Heat Biologics Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity and Delayed Tumor Progression at American Association for Cancer Research (AACR) Annual Meeting 2021

    DURHAM, NC / ACCESSWIRE / April 12, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today reported that promising new preclinical data of PTX-35 is presented at the AACR Annual Meeting 2021.

    View More →
  • Heat Biologics Provides Year-End Business Update

    DURHAM, NC / ACCESSWIRE / March 25, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today provided financial, clinical and operational updates for the year ended December 31, 2020.

    View More →
  • Heat Biologics to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

    DURHAM, NC / ACCESSWIRE / March 8, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that Jeff Wolf, CEO of Heat Biologics, has been invited to present at Inaugural Emerging Growth Virtual Conference, hosted by M Vest LLC and Maxim Group LLC.

    View More →
  • HTBX: HS-110 Phase 2 Interim Data

    By John Vandermosten, CFA NASDAQ:HTBX READ THE PREVIOUS HTBX RESEARCH REPORT HS-110 Interim Data Heat Biologics, Inc. (NASDAQ:HTBX) announced positive interim survival data for its Phase II trial of HS-110 (viagenpumatucel-L), a cell-based therapy, in combination with leading checkpoint blockade inhibitors (CBIs). The trial was not a comparator trial; however, similarities in design with past

    View More →
  • Heat Biologics to Present at 2021 BIO CEO & Investor Digital Conference

    DURHAM, NC / ACCESSWIRE / February 12, 2021 / Heat Biologics, Inc. ("Heat") (Nasdaq:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product .

    View More →
  • Is Heat Biologics Stock a Buy Right Now? Analyst Weighs In

    Tuesday was a good day for investors of Heat Biologics (HTBX). Shares blasted off by 50%, after the biotech company announced positive interim data for its lung cancer treatment. Specifically, in the Phase 2 trial of HS-110, in combination with Bristol-Myers Squibb's OPDIVO (nivolumab) in advanced non-small cell lung cancer (NSCLC), there was a significant improvement to survival rates when the two treatments were put to work together. HS-110 is an allogeneic cell-based therapy intended to strengthen the immune system to target cancer cells. Opdivo, is a checkpoint inhibitor. When combined, there was a median overall survival of 24.6 months, compared to the median overall survival of 12.2 months when just using Opdivo. Additionally, the combination resulted in a one-year survival rate of 61.7% vs. the 50.7% rate exhibited by Opdivo on its own. The data also showed that NSCLC patients could still benefit from HS-110, even though the disease had progressed following checkpoint inhibitor therapy. B. Riley analyst Mayank Mamtani says the data confirms HS-110’s standing as a “partner of choice” in the treatment of NSCLC. “We believe the data... serves as further validation for HS-110's positioning in a relatively busy advanced NSCLC landscape and provides supportive evidence to the ongoing engagement with FDA on clarifying the path to registration in a pivotal Ph. III study,” the 5-star analyst noted. “HS-110 update also serves to de-risk and showcase the broad utility of the gp96 platform, which is also behind the design of HTBX’s COVID-19 vaccine candidate.” HTBX recently announced the completion of its gp96-based Covid-19 vaccine cell line. The company is developing the vaccine, called ZVX-60, for use as a standalone jab or to be used with other vaccine candidates to strengthen prophylactic protection. The company plans to initiate a Phase 1 study by mid-2021. If you think you might have missed the boat following Tuesday’s surge, then Mamtani thinks otherwise. The analyst has a $20 price target for the shares, implying further upside of 80% from current levels. Unsurprisingly, Mamtani’s rating stays a Buy. (To watch Mamtani’s track record, click here) The B. Riley analyst is not alone in predicting a bright future for HTBX. 4 other analysts recently reviewed the company’s prospects, and all reached the same conclusion – Buy. The Strong Buy consensus rating is backed by a bullish average price target; At $26.25, there’s potential for a hefty 138% upside potential in the year ahead. (See HTBX stock analysis on TipRanks) To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

    View More →
  • Heat Biologics Stock Notches Scorching RS Rating

    On Wednesday, Heat Biologics got a positive adjustment to its Relative Strength (RS) Rating, from 89 to 96. The high RS Rating makes Heat Biologics stock one for your market rally watchlist. As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.

    View More →
  • Heat Biologics Catapults After Drug Regimen Boosts Lung-Cancer Survival

    Heat Biologics said Tuesday adding its experimental drug to Bristol Myers Squibb's Opdivo helped more lung-cancer patients survive. In response, HTBX stock catapulted.

    View More →
  • Heat Biologics Pops 77% On ‘Positive’ Lung Cancer Therapy Trial Data

    Heat Biologics shares spiked 77% as the biopharma company reported positive interim data from the Phase 2 trial of its lung cancer treatment. The Phase 2 trial tested Heat’s (HTBX) HS-110 in combination with Bristol Myers Squibb’s opdivo (nivolumab) as a therapy for the treatment of patients with advanced non-small-cell lung cancer (NSCLC). HS-110 is Heat’s “off-the-shelf” cell-based therapy tailored to activate a patient’s immune system and induce a robust response against tumor cells. Heat Biologics CEO Jeff Wolf said that the findings of the Phase 2 trial data demonstrate “...HS-110’s broad potential for providing multiple treatment options to NSCLC patients.” “We are currently evaluating possible Phase 3 registration pathways for HS-110 in combination with a checkpoint inhibitor and intend to review these plans with the FDA as well as potential partners,” Wolf added. The Phase-2 trial results showed a one-year survival rate of 61.7% for patients who were given HS-110 in combination with Bristol Myers Squibb’s (BMY) opdivo. These patients had advanced NSCLC but were not given a checkpoint inhibitor. A checkpoint inhibitor is a drug that blocks proteins on the surface of immune system cells like the T-cells from binding with proteins on the surface of a tumor cell. Heat has a number of candidates in its product pipeline, including a COVID-19 vaccine. On Jan. 19, the company announced the initiation of the manufacturing process of its ZVX-60 vaccine. Maxim Group analyst Jason McCarthy last month lowered the stock’s price target from $35 to $22 but reiterated a Buy rating on the stock. McCarthy said, “the opportunity for Heat’s gp96-based vaccine approach is still intact and on 1/19 the company moved a step closer to the clinic with the commencement of manufacturing its COVID-19 vaccine cell line ZVX-60.” (See Heat Biologics stock analysis on TipRanks) The rest of the Street is in line with McCarthy’s view with a Strong Buy consensus rating. That’s based on 4 analysts recommending a Buy. The average analyst price target of $26.25 implies 214% upside potential to current levels. Related News: Cubic Inks $2.8B Buyout Deal With Veritas Capital, Evergreen; Shares Spike 10% Palantir Partners With IBM To Provide AI-Driven Business Solutions Coherent Gets $6B Rival Buyout Offer From MKS; Shares Jump 13.6% More recent articles from Smarter Analyst: Coty Tanks 14% As Quarterly Sales Fail To Impress; Street Says Hold DoorDash To Snap Up Robotics Startup Chowbotics Coherent Gets $6B Rival Buyout Offer From MKS; Shares Jump 13.6% Tuesday’s Pre-Market: Here’s What You Need To Know Before The Market Opens

    View More →
  • Heat Biologics Cell Therapy Shows Survival Benefit In Mid-Stage Lung Cancer Study, Shares Rally

    Heat Biologics Inc (NASDAQ: HTBX) soars in premarket on the heels of encouraging interim data from the Phase 2 trial evaluating HS-110, in combination with Bristol-Myers Squibb's (NYSE: BMY) Opdivo (nivolumab) in advanced non-small-cell lung cancer (NSCLC). Median progression-free survival (PFS) of 1.8 months and median overall survival (OS) of 24.6 months was observed in checkpoint inhibitor naïve patients with advanced NSCLC (cohort A, N = 47). The one-year survival rate of Cohort A is 61.7%. The median OS data was 12.2 months, and the 1-year survival rate was 50.7% in previously treated, advanced NSCLC patients who received nivolumab as a single agent, according to published data of the CheckMate 057 study1. For NSCLC patients who had previously been treated with a checkpoint inhibitor and whose disease had subsequently progressed (Cohort B, N = 68), a median PFS of 2.8 months and median OS of 11.9 months was observed. As of this data cut, 30% of the patients in Cohort A and 26% of Cohort B patients are still alive. HS-110 showed a favorable safety profile and has been administered in approximately 200 patients to date. No treatment-related serious adverse reactions were reported. HS-110 is an "off-the-shelf" allogeneic cell-based therapy designed to activate patients' immune system against multiple cancer-testis antigens to elicit a diverse and robust immune response against tumor cells. Price Action: HTBX gained almost 80% to $15.1 during the premarket session on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaOpdivo Plus Cabometyx Combo Shows Superior Clinical Benefit Versus Sunitinib In Late-Stage Kidney Cancer Study© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Heat Biologics Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial

    6 months in previously treated checkpoint inhibitor naïve non-small cell lung cancer patients who received HS-110 in combination with nivolumabDURHAM, NC / ACCESSWIRE / February 9, 2021 / Heat Biologics, Inc. ("Heat")(NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today reported positive interim data of the Company's fully-enrolled Phase 2 trial of HS-110, in combination with Bristol-Myers Squibb's (BMS) OPDIVO® (nivolumab) in advanced non-small cell lung cancer (NSCLC).

    View More →